Compugen Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CGEN research report →
Range $5 – $5
Price Chart
About the company
Compugen Ltd. , an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe.
- CEO
- Eran Ophir
- IPO
- 2000
- Employees
- 75
- HQ
- Holon, TA, IL
Get TickerSpark's AI analysis on CGEN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $174.29M
- P/E
- 4.73
- PEG
- 0.02
- P/S
- 2.30
- P/B
- 2.09
- EV/EBITDA
- 4.81
- Div Yield
- 0.00%
- Gross Margin
- 86.23%
- Op Margin
- 41.28%
- Net Margin
- 47.90%
- ROE
- 39.30%
- ROIC
- 29.70%
Latest fiscal year · YoY change
- Revenue
- $72.76M+161.1%
- Gross Profit
- $63.51M+218.6%
- Op Income
- $31.33M
- Net Income
- $35.34M+348.4%
- EPS
- $0.38+337.5%
- OCF Growth
- -36.2%
- FCF Growth
- -36.7%
- 52W High
- $3.24
- 52W Low
- $1.43
- 50D MA
- $2.14
- 200D MA
- $2.30
- Beta
- 2.82
- RSI (14)
- 35
- Avg Volume
- 223.56K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Compugen said it remains on track for key 2027 data readouts, while cash runway now extends into 2029 and partnered programs continue advancing.· November 9, 2026
- MAIA-Ovarian is fully enrolled, with randomized data for COM701 still expected by the end of Q1 2027.
- Compugen reiterated a 2027-heavy catalyst calendar, including AstraZeneca’s ARTEMIDE-Biliary01 Phase III readout now expected in 2H 2027.
- Cash and investments were about $117.5 million at September 30, 2026, and management said the runway funds operating plans into 2029 assuming no further inflows.
- Q3 revenue was about $3.8 million, up from about $1.9 million a year ago, driven by recognition from the Gilead agreement.
- The company launched UnigenX to expand target discovery into tumor-associated antigens for modalities such as T-cell engagers.
Third-quarter 2026 revenue was approximately $3.8 million versus approximately $1.9 million in the same quarter of 2025. R&D expense was approximately $5.8 million, flat year over year, and G&A expense was approximately $2.3 million versus $2.2 million last year. Net loss was approximately $5.8 million, or $0.06 per basic and diluted share, compared with a net loss of approximately $7 million, or $0.07 per basic and diluted share, in Q3 2025. As of September 30, 2026, cash, cash equivalents, short-term bank deposits and marketable securities were approximately $117.5 million. Management said this cash position is expected to fund operating plans into 2029 assuming no further cash inflows. Forward-looking items include COM701 MAIA-Ovarian data by the end of Q1 2027 and AstraZeneca’s ARTEMIDE-Biliary01 high-level results in 2H 2027.
Eran Ophir emphasized three main progress points: MAIA-Ovarian is fully enrolled and on track for data by the end of Q1 2027, partnered programs continue to advance, and UnigenX expands the company’s discovery engine into tumor-associated antigens. His tone was constructive and development-focused, with 2027 presented as a data-rich year for the company. He also framed COM701 as differentiated by safety and potential to extend the platinum-free interval in ovarian cancer.
David Silberman described the balance sheet as solid, citing approximately $117.5 million in cash, cash equivalents, short-term bank deposits and investments in marketable securities at September 30, 2026. He said the company’s runway, assuming no further cash inflows, is expected to fund operating plans into 2029. He also noted Q3 revenue of approximately $3.8 million, R&D of approximately $5.8 million, G&A of approximately $2.3 million, and net loss of approximately $5.8 million, with expenses in line with plans.
Analysts focused on the new UnigenX platform, asking how it differs from Unigen, when new clinical candidates might emerge, and whether the approach is centered on neoantigens or HLA-presented peptides. Ophir said UnigenX is an expansion of Unigen into tumor-associated antigens for highly selective targets, especially for T-cell engagers, but did not give timing for new candidates. Another question centered on the ARTEMIDE-Biliary01 readout and whether it triggers a payment; Ophir said the next milestone is BLA acceptance and referenced an added $25 million tied to that milestone. On GS-0321, management declined to discuss the biologically active dose or disclosure timing, saying Gilead approval is required.
The call reinforced a strong 2027 catalyst slate: COM701 data, AstraZeneca’s biliary tract cancer readout, and continued advancement of partnered assets. Management also pointed to a healthy cash position and runway into 2029, reducing near-term financing pressure. UnigenX could broaden the pipeline if it successfully identifies new tumor-associated antigens for selective immune-targeting approaches.
The core value driver, COM701, still has no efficacy data yet; investors must wait until the end of Q1 2027. The company also gave limited visibility on GS-0321 timing and clinical disclosure because Gilead controls the asset, which leaves another program harder to underwrite. For COM701, management’s own working assumption was that the placebo arm may have median PFS around 4 months, underscoring that the bar may still be meaningful despite the unmet need.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 94.72M
- Float Shares
- 94.37M
of shares held by institutions
87 13F filers
Buy/sell ratio 11.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Silverarc Capital Management, LLC | 3.59M | ▲ 402.53K |
| Renaissance Technologies LLC | 1.54M | ▼ 333.30K |
| Nomura Asset Management International Inc. | 1.02M | 0 |
| Morgan Stanley | 970.61K | ▼ 81.38K |
| Ark Investment Management LLC | 887.87K | ▲ 101.33K |
| Taylor Frigon Capital Management LLC | 816.25K | ▼ 25.93K |
| Two Sigma Investments, LP | 512.42K | ▼ 9.17K |
| Altshuler Shaham Ltd | 450.63K | ▼ 71.00K |
| State Street Corp | 434.47K | ▲ 18.81K |
| Atom Investors LP | 303.53K | ▲ 258.15K |
| Arrowstreet Capital, Limited Partnership | 265.81K | ▲ 265.81K |
| Ubs Group AG | 263.56K | ▼ 12.11K |
Held by 6 ETFs
Biggest fund positions in CGEN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 29, 26 | Levine Zurit | other | 18,000 |
| Jul 29, 26 | Levine Zurit | other | 24,000 |
| Jul 29, 26 | Silberman David | other | 19,500 |
| Jul 29, 26 | Silberman David | other | 26,000 |
| Jul 29, 26 | Ophir Eran | other | 200,000 |
| Jul 29, 26 | Cohen-Dayag Anat | other | 100,000 |
| Jul 29, 26 | Perry Eran | other | 7,500 |
| Jul 29, 26 | Perry Eran | other | 10,000 |
| Jul 29, 26 | Ferre Pierre | other | 70,000 |
| Jul 29, 26 | Kredo Russo Sharon | other | 18,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CGEN coverage
Recent articles, reports, and earnings notes.
No research on CGEN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CGEN report →Compugen: COM701 Data On Track And Continued Bispecific Rilvegostomig Development
seekingalpha.com · Nov 10
Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit
prnewswire.com · Nov 10
Compugen Ltd. (CGEN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
What Compugen (CGEN) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Compugen (CGEN) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 9
Compugen Reports Third Quarter 2026 Results
prnewswire.com · Nov 9
Compugen to Participate in November Investor Conferences
prnewswire.com · Nov 3
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
defenseworld.net · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.